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Abstract 
Ernesto Marques, PhD 
 
Zika Virus Infection Modulates Expression of Regulatory Complement Factors in SH-
SY5Y Cells 
 
Jason Yeung, MS 
 
University of Pittsburgh, 2020 
 
Abstract 
 
 
Viruses that use the blood as a route of systemic spread frequently encode proteins allowing 
evasion of the complement system. Although complement neutralizes pathogens in the blood, the 
complement system has non-immune functions in the central nervous system (CNS) and mediates 
non-viral neuropathologies when triggered by damaging stimuli.  
As viruses capable of both hematogenous spread and neuroinvasion, flaviviruses such as 
Zika virus (ZIKV) are a significant public health issue as the most common cause of arboviral 
disease. Outside of the brain, flaviviruses can modulate levels of complement proteins and surface 
bound complement regulators. We hypothesized that similar alterations occur in CNS cells, 
contributing to viral neuropathology.  
In this study, we establish the relevance of viral complement modulation in infection of 
CNS cells. Using various CNS culture systems, endogenous expression of complement proteins 
and complement-related surface markers was investigated.  In a co-culture system of cell lines SH-
SY5Y (neuroblastoma) and HMC3 (microglia), endogenous complement protein production was 
confirmed in absence of Zika infection and stimulation. Furthermore, Zika infection modulated 
expression of surface bound inhibitors CD46 and CD55. Compared to mock, CD46 was 
upregulated in both infected and non-infected, bystander cells with stronger expression in infected 
 v 
cells. CD55 was equally downregulated in infected and bystander cells. Finally, affinity between 
ZIKV non-structural protein 1 (NS1) and complement proteins was demonstrated.  
These results support previous studies implicating complement modulation as a source of 
pathology in neuro-invasive flavivirus infection, providing insight on the precise biochemical 
changes behind this process. 
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1.0 Introduction 
Circulation of Zika virus (a flavivirus) is concerning in light of its association with severe 
neurologic and neuro-developmental disease (1, 2). Currently, there are no approved treatments or 
vaccines available to address disease caused by Zika virus. In the context of central nervous system 
(CNS) infection, identifying sources of pathogenesis could inform treatment strategies as well as 
vaccine design. 
The complement system, a key part of the innate immune system, achieves a dynamically 
regulated balance which is perturbed in response to pathological or pathogenic insult. Accordingly, 
previous studies have implicated complement overactivation and dysregulation in severe flaviviral 
disease in and outside of the CNS (3, 4). However, the complement system has also been revealed 
to have key roles in normal functioning and development of the human brain (5-7). While finely 
controlled complement processes serve to maintain cellular health, overactivation of complement 
has been associated with disease-causing processes such as neurodegeneration (8-10). 
These results lead us to hypothesize that dysregulation of complement plays an important 
role in Zika pathology of the brain. The connections between flaviviruses, complement, and the 
specific context of the CNS will be explored (Figure 1). 
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1.1 Complement: Multiple Functions in the Immune System and CNS 
1.1.1 Complement in the Periphery 
Complement proteins have traditionally been regarded as soluble, serum factors circulating 
throughout the body (Figure 1). Comprised of over 60 factors and receptors, new functions for 
complement are being discovered despite early recognition of its role in the blood. Such functions 
span immunity, wound healing, cell homeostasis, and differentiation (11).  
Principles of the complement system echo those of intracellular signaling pathways. 
Complement proteins function as proteases, amplifying localized production of active components 
Figure 1 Distinct Roles for Complement in Immunity and Neurodevelopment Interact in the CNS 
Complement has immune and neurodevelopmental functions which share common regulatory programs. During 
infection, these functions are hypothesized to intersect, potentially leading to poor outcomes. 
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through cascades. There are three main pathways initiating the complement cascade—the classical, 
lectin, and alternative pathways.  
• The classical pathway is initiated by binding of the C1 complex to a variety of ligands 
including pathogen associated molecules, C-reactive protein, and antibodies (primarily IgG and 
IgM).  
• The lectin pathway recognizes carbohydrate groups on cells through mannose binding 
lectin (MBL) or ficolin.  
• The alternative pathway primarily serves as an amplification loop for the other pathways 
although spontaneous activation of the alternative pathway can occur through hydrolysis of C3.  
These three processes of initiation feed into a common pathway, typically leading to either 
formation of the terminal complement complex (TCC) or complement-enhanced phagocytosis 
upon successful activation. C3 and C5 cleavage also results in the production of anaphylotoxins 
C3a and C5a, both potent inducers of inflammation.  
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Figure 2 Overview of the Complement System 
The three complement pathways differ in initiation but link to a common pathway downstream of C3. Various 
byproducts produced during these pathways have corresponding receptors, initiating cellular programs. Cells under 
homeostatic conditions retain surface-bound regulators of complement. Abbreviations: AP, alternative pathway; C1-
INH, C1 inhibitor; C3aR, C3a receptor; C4BP, C4b-binding protein; C5aR, C5a receptor; C5L2, C5a receptor-like 2; 
Clu, clusterin; CP, classical pathway; CPN, carboxypeptidase-N; CR, complement receptor; FB, factor B; Fcn, 
ficolins; FD, factor D; FH, factor H; FI, factor I; LP, lectin pathway; MAC, membrane attack complex; MASP, MBL-
associated protease; MBL, mannose-binding lectin; RCA, regulator of complement activation; Vn, vitronectin (12) 
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Recently, an intracellular activation pathway termed the “complosome” has been 
described. Active components of complement—cleaved C3 and C5—have been identified inside 
T and B cells (13). Furthermore, intracellular localization of C3b has been found in isolated 
monocytes, neutrophils, epithelial cells, endothelial cells, and fibroblasts (14). In lymphoid-
derived cells, this activation promotes effector functioning and cell homeostasis. However, the 
broad consequences of complosome activation in other cells have yet to be determined.  
Rather than inert, C3 is continuously cycled and cleaved during homeostatic conditions. 
Defined as C3 “tick-over”, this occurrence permits rapid responsiveness of the alternative pathway 
(15, 16). An apt metaphor is that of a sonar system which detects objects by constantly surveilling 
the environment (17). Deposition and turnover of soluble complement occurs at a steady rate, 
decoupled from effector functions by local complement regulatory factors. Only when cleaved 
products accumulate past a threshold do these functions trigger. Reasonably, the balance between 
pro-activation members and regulatory proteins must be carefully maintained to prevent non-
specific complement engagement. 
Naturally, there are several proteins involved in regulation of the different pathways (Table 
1). Regulation of the complement system largely occurs through inhibition of cleavage, cleavage 
to inactive products, dissociation of active complexes, or context-specific expression. Regulatory 
factors act at different stages of activation, allowing for tight control under homeostatic conditions. 
A key regulatory axis involving CFI occurs on the surface of C3b-bound cells. Complement factor 
I (CFI) converts C3b to iC3b with the assistance of complement factor H (CFH) and CD46, 
steering the cascade away from TCC formation but towards phagocytosis mediated by iC3b 
recognizing receptors such as complement receptor 3 (CR3; composed of CD11b and CD18) (18). 
Another axis involves depolymerization of C3 convertases. C4b-binding protein (C4BP), CFH, 
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and CD55 act to prevent further deposition of activated complement fragments, leading to 
resolution of the cascade. Finally, regulators CD59, vitronectin, and clusterin directly prevent TCC 
formation by competing with active components. Of these diverse regulators, surface-bound 
CD46, CD55, and CD59 act to limit off-target complement activation on bystanders (19). 
1.1.2 Complement in the Brain 
Besides providing protection against pathogens, complement is involved in regulated 
processes of neural development and homeostasis—specifically neuronal differentiation, 
proliferation, migration of progenitors, and synaptic pruning. However, complement also 
contributes to neurodegenerative diseases with the complement system playing a role in a wide 
array of CNS-related conditions including Alzheimer’s, multiple sclerosis, and ischemic stroke 
(20-23). Consequently, perturbation of complement’s natural balance could lead to some of the 
neurological complications found in adult Zika infection and congenital Zika syndrome (CZS).  
In the periphery, a variety of cell types produce complement proteins although the liver is 
primarily involved in complement biogenesis and is the main source of serum C3 (24). As serum 
proteins experience difficulty crossing the intact BBB, complement factors of the brain are 
regarded as being produced within the CNS (25).  
Throughout the brain, complement factors and corresponding receptors are expressed by 
discrete cell populations. As immune-responsive cells, neurons and astrocytes both produce select 
complement components as well as factors modulating complement expression (26-28). Microglia 
additionally display surface receptors for activated complement products and dynamically respond 
to the complement milieu. Based on preliminary in vitro studies conducted in the Marques and 
Nimgaonkar lab, neurons and microglia are likely sources of C3, C1Q, and C4 in the CNS 
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(Unpublished). Additionally, co-cultures of pluripotent stem cell-derived neurons, astrocytes, and 
microglia demonstrate minimal to no levels of terminal complement proteins.  Consequently, the 
CNS may limit terminal complement formation by selective expression of components and 
experimental findings indicate a lack of polymerized terminal complement components (C5b9) in 
the brain when BBB integrity is maintained. Although not definitive, BBB integrity may influence 
levels of complement within the CNS, confounding claims of endogenous production (29). Finally, 
it is unclear if complement levels in the brain and cerebrospinal fluid (CSF) are high enough to 
meaningfully impact viral titers via neutralization; whereas incubation of virus with complement-
containing serum clearly reduces infectivity, similar experiments using CSF have not been 
conducted or are obscure. 
Complement patterns the developing brain, promoting cell-specific migration and 
differentiation. Early evidence for a complement developmental axis was derived from 
phenotyping of knockout mice. Knockout mice for various complement factors of the classical and 
lectin pathways exhibit impaired neuronal development with behavioral abnormalities. 
Involvement of the alternative pathway appears limited; knockout mice of Factor B, an essential 
component of the alternative pathway, develop normally with no reproductive or behavioral 
abnormalities (30).  
The developmental functions of complement are linked to generation of anaphylotoxins, 
C3a and C5a. C3a signaling in the neural crest was found to promote cell migration of neural crest 
cells (7). Additionally, the lectin pathway (initiated by MASP-1 and -2) is integral for C3a-
dependent neuronal migration. Expression of complement proteins is highly regulated temporally 
and spatially in these processes. Gorelik et al. interrogated transcriptional dynamics of Masp-1, 
Masp-2, C3, C3aR and C5aR using fetal tissues and found expression levels to be dependent on 
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developmental stage (31). MASP-1, MASP-2, and C3 were expressed in a radiating pattern 
throughout the fetal brain with low levels of expression in the ventricular zone and higher levels 
near the cortical plate (31).  
Unlike C3a which plays a role in cell migration, C5a is involved in proliferation and 
differentiation. It is suspected that production of C5 occurs in an autocrine manner from hNPCs in 
neural rosettes. Mice studies have demonstrated C5a signaling through C5aR1 promotes hNPC 
proliferation and maintains cell polarity (32). These events are spatially limited to the apical 
(facing the lumen) surface of the ventricular zone and temporally limited to early stages of neural 
development as expression of both C5 and C5aR1 decrease after hNPCs differentiate. Finally, C5a 
appears at higher levels within CSF of developing embryos than adult CSF, mirroring its role in 
early development (32). 
Synaptic pruning describes the coordinated removal of a synapse between two neuronal 
cells. This process contributes to key cognitive phenomena such as learning and forgetting but 
cognitive impairment when dysregulated (33). Physiologically, synaptic pruning matures neuronal 
circuitry by removing “excess” connections (Figure 3). 
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Figure 3 Synaptic Pruning Relies on Elements of the Complement System 
Left: In the absence of activated complement, synapses remain stable. In the developing retina, astrocytes can induce 
expression of C1q in retinal ganglion neurons through TGF-β. Neuron and/or microglial C1q will initiate the classical 
cascade on synapses to be pruned. Synapses covered in C3b products are subject to phagocytosis. Right: 
Neurodegenerative pruning involves similar effectors. Reactive phenotypes for microglia and astrocytes are highly 
inflammatory and lead to the upregulation of cytokines (“X”) and complement factors. Secretion of these factors 
instigates complement activation and loss of synapses in pathological conditions (27). 
 
Under homeostatic conditions, less active synapses trigger the process of pruning.   
Although details remain unclear, current models assert under-utilized synapses initiate crosstalk 
with adjoining astrocytes and microglia (34). Crosstalk—entailing the exchange of soluble 
factors—enables surface expression of pro-phagocytic proteins (“Eat me” signals), reduction of 
anti-phagocytic markers (“Don’t eat me”), increased soluble complement, and chemoattraction of 
microglia to the synapse (35). Following migration, synaptic pruning is believed to function 
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through microglial phagocytosis enhanced by the classical pathway (6, 9). Consequently, C1q and 
C3 have been implicated as mediators.  
Microglia are the primary source of C1q as microglial-specific deletion in mice results in 
near complete ablation of C1q production in the brain (36). Retinal ganglion neurons are also 
capable of C1q expression in presence of astrocyte-derived TGF-β (26). While C1q deposition on 
synapses initiates the classical pathway and subsequent C3 deposition, C1q binding elicits other 
direct effects. C1q deposition leads to local activation of apoptosis-like processes in axons and the 
corresponding receptor C1qR enhances phagocytosis upon ligation, both potentially promoting 
engulfment independent of downstream C3 cleavage (37, 38). However, C3 clearly plays a role in 
many pruning or pruning-like mechanisms. Blockage of CR3 (which recognizes surface iC3b) on 
microglia abrogated synaptic pruning (6). It is unclear if the alternative pathway can effectively 
initiate synaptic pruning during physiologic pruning. However, such initiation may be feasible in 
multiple sclerosis as evidenced by mice demonstrating C3 but not C1q on actively pruned synapses 
and synapse loss in C1qa knockout mice (23, 39).  
1.2 Flaviviruses 
1.2.1 Clinical Spectrum of Zika CNS Infection 
While the existence of ZIKV was known since 1947, research was minimal until the World 
Health Organization declared ZIKV an international health emergency. During the 2015 ZIKV 
outbreak, incidence of severe neurological symptoms alarmed health professionals around the 
world. Coupled with a propensity for mild or asymptomatic acute infection, diagnosis of ZIKV 
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infection in early stages can be challenging. More recently, clinical and experimental evidence 
suggests ZIKV can induce pathology within the brain (with associated neurodevelopmental or 
cognitive delay) in the absence of other overt symptoms (40-42). The possibility of such “silent 
pathologies” have drawn attention in both children and adults (Figure 4). 
 
Figure 4 Clinical Manifestations of Zika Infection 
The vast majority of Zika infections are asymptomatic. In rare instances, patients can manifest severe neurologic or 
neurodevelopmental symptoms (43). 
   
Recognition of an association between ZIKV infection and microcephaly fueled global 
concern during the Brazilian outbreak.  However, the consequences of fetal ZIKV infection 
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(termed congenital Zika syndrome [CZS]) represent a broad spectrum of neurological 
presentations. This heterogeneity is associated with time of maternal infection due to the uneven 
timing of human neurogenesis, the bulk of which occurs before gestational week 25 (44). One of 
the earliest post-mortem studies of a ZIKV-infected neonate, Mlakar et al. presented findings of 
complete agyria, regions of calcification, ventriculomegaly, diffuse microglial and macrophage 
infiltration, yet a general lack of inflammation (45). Driggers et al. described a single case 
exhibiting smaller brain size, calcification, diffuse infiltration of macrophages, and partially 
differentiated neuronal cells in the neocortex (1). Through pathological examination of ten ZIKV-
infected neonates, Chimelli et al. categorized cases into three groups: neonates with severe 
ventriculomegaly; neonates with low total brain mass and mild to moderate ventriculomegaly; and 
neonates with localized calcification yet little overall morphological change (41). This third group 
was associated with maternal exposure in late-term pregnancy. In aggregate, these diverse 
pathologies most commonly manifest as neurodevelopmental delay and ophthalmic abnormalities 
(43). Although no analogous evidence exists in humans,  infection of animal models in early life 
also leads to poor outcomes with both mice and rhesus macaque models demonstrating behavioral 
abnormalities and persistent anatomical changes in the brain (46, 47). 
Adult CNS infections can lead to equally diverse outcomes with findings such as 
encephalitis, meningoencephalitis, and myelitis (48, 49). An atypical Guillain-Barre syndrome 
demonstrating CNS involvement is also possible leading to functional changes detectable by 
neuroimaging in the acute period (50). While neurological symptoms in adult infection are 
relatively rare, it is possible silent pathologies exist in adult infection as well.  Adult mice models 
of CNS infection demonstrate memory decline in absence of mortality (42, 51).  
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1.2.2 Zika virus tropism in the brain 
Neuroinvasion is exhibited by many flaviviruses. West Nile, Zika, Japanese encephalitis 
virus, and tick-borne encephalitis virus clearly demonstrate neuro-invasiveness although Dengue 
and Yellow Fever viruses are capable of CNS infection (52, 53). 
In maternal infection, the mechanism ZIKV uses to gain access to the fetal brain is still 
undescribed. The route from site of maternal exposure to the fetal brain is a circuitous one. ZIKV 
infection presumably spreads through systemic maternal circulation, bypasses the placental 
interface, enters fetal systemic circulation, bypasses the fetal blood brain barrier (BBB), and 
penetrates deeper into the CNS. This path necessitates circumvention of two cellular barriers: the 
placenta and fetal blood brain barrier. Accordingly, flaviviruses are highly capable of 
circumventing immunity at cellular barriers with such bypass linked to flaviviral nonstructural 
protein 1 (NS1) (54, 55).  
Bypass of the BBB could be destructive or non-destructive. BBB breakdown was 
demonstrated in adult mice models, allowing infiltration of leukocytes into the CNS (56). 
However, degradation could be secondary to ZIKV bypass of the BBB. Infection of human brain 
microvascular endothelial cells simulating the BBB in vitro allowed passage of competent ZIKV 
into the CNS with minimal disruption (57, 58). Correspondingly, variable levels of BBB 
permeabilization or damage were demonstrated in animal studies (56, 59, 60).  
Neurotropism of ZIKV has been demonstrated in vivo and in vitro. Several experimental 
models including mice, non-human primates, explants, and human organoids exhibit active 
replication in CNS cells with maternal or direct inoculation (61-65). Neurons, neuroprogenitor 
cells, neural stem cells, astrocytes, and microglia are all susceptible to ZIKV infection. Once 
infection is established within the brain, virus can persist despite clearance in the periphery (66). 
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 Tropism across models is relatively consistent. Myelinating cultures showed wildtype and 
Ifnar1-deficient mice CNS but not PNS cells were ZIKV permissive (67). In adult Ifnar -/- mice, 
astrocytes and neurons could support viral growth, a pattern seen throughout the brain (56). 
Isolated human fetal brain phagocytes including microglia demonstrated susceptibility to viral 
infection (65). ZIKV can also stably infect human neuroprogenitor cells (hNPC) in vitro, affecting 
their differentiation and growth (68, 69). Lin et al. included comprehensive immunostaining of 
fetal tissues from second trimester donors, presenting a more nuanced view of hNPC tropism. In 
accordance with in vitro models, intermediate progenitor cells (a type of hNPC) appeared highly 
permissive to ZIKV. However, the sparse co-localization of ZIKV envelope protein and either 
SOX2 or nestin found in donor brains suggest neuroepithelial cells and radial glial cells (also 
hNPCs) were largely un-infected. Lin et al. confirmed that while hNPCs were permissive in the 
context of neural monolayers, hNPC infection was rarer in donor samples. The absence of infected 
hNPCs has been interpreted as rapid depletion of this population, perhaps providing a basis for 
cortical thinning observed in CZS (70). Adult infection is believed to similarly deplete hNPCs, a 
cell population which contributes to plasticity and regeneration in the mature brain (62). 
1.2.3 Flavivirus immunity in the matured brain 
Bypass of the BBB is accompanied by establishment of infection, activation of local 
immune responses, and infiltration of immune cells into the CNS. Once brain resident cells are 
infected, viral detection through pathogen recognition receptors such as TLR3 leads to local 
immune responses and apoptosis (71, 72). Consequently, several cytokines are produced and 
secreted during CNS infection.  
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Neurons, astrocytes, and microglia all express various receptors for cytokines (73). 
Cytokine production instigates both expression of anti-viral proteins as well as engagement of 
innate immune effector cells. Type I interferon signaling, a major player in early response to viral 
infection, potently restricts flaviviral replication but is efficiently antagonized by multiple 
flaviviral proteins (74-76). Additional cytokines orchestrate the host response within the brain. 
Elevated soluble IL-6, IL-10, and IFN-γ was found in CSF of Zika-positive pediatric encephalitis 
patients (77). However, elevated levels of IL1β and TNF-α were detected in ZIKV-infected 
neuronal cultures and brains of mice but not in CSF of rhesus macaques (42, 66, 78).  
After the early stages of infection, cells infiltrate the brain and adopt an active phenotype, 
eliciting cellular immunity. For ZIKV, CD8+ cells can appear in large number within the brain 7 
days post infection. The predominant infiltrating cell population in Ifnar -/- mice shifts with 
macrophages and polymorphonuclear leukocytes (PMNs) composing the majority earlier in 
infection (day 5) and CD8+ cells later (day 7) (56). However, type I interferon deficiency is a 
crucial caveat to these results and may limit generalization to human infection. In 
Manangeeswaran et al., the majority of infiltrating cells in one day old wildtype mice were CD4+ 
or CD8+ whereas PMNs predominated in Ifnar -/- mice 15 days post infection, supporting distinct 
immune responses (79). 
Infiltrating cells have distinct functional niches during CNS flavivirus infection. 
Phagocytes from the periphery and microglia migrate to the site of infection, secrete antiviral 
cytokines, and serve as antigen presenting cells—linking innate responses to adaptive immunity. 
Dengue encephalitis models demonstrate the critical importance of microglia in controlling viral 
titers in the brain (80, 81). Microglia-mediated protection heavily relies on subsequent infiltration 
of IFN-γ+ CD8+ cells (51, 81). Activated microglia present antigen to infiltrating T cells, 
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upregulating molecules associated with antigen presentation such as CD80, CD86, and MHC class 
II (81). Activation of T cells can mediate cytolytic and non-cytolytic viral control, in turn 
producing cytokines acting on neurons, glia, and leukocytes. Despite their contribution to viral 
clearance, cytotoxic T cells may also contribute to certain ZIKV-associated neurological 
complications. Adult ZIKV-infected Ifnar -/- mice experience hindlimb paralysis upon infection, a 
symptom which does not develop in CD8+ depleting conditions (56).  
1.2.4 Role of Complement in Flaviviral Pathogenicity 
Involvement of the complement system in flaviviruses related to ZIKV such as West Nile 
Virus (WNV) and Dengue virus (DENV) has been experimentally confirmed with many 
foundational studies originating from the Diamond lab. Of the two related viruses, WNV is of 
particular interest due to its neuroinvasiveness and the well-established role of complement in the 
development of chronic neurologic symptoms. Additionally, flaviviral nonstructural protein 1 
(NS1) has affinity for several complement proteins and can influence complement activation 
(Table 1). 
 
Table 1 Flavivirus Non-structural Protein 1 Interactions with Complement 
 
 
 
 
 
 
DENV MBL (82), Vitronectin, C5, C6, C7, C9 (83),  C1Q (84, 85), C4 (86), C4 
+ C1S (87), C4BP (82) 
 
WNV Factor H (88), C4 + C1S (87), C4BP (82) 
YFV C4 + C1S (87), C4BP (82) 
ZIKV C1Q (85) 
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All three complement pathways have been evaluated in mice models of WNV infection. In 
serum, the classical pathway primes T cell responses and limits viral pathogenicity (89, 90). In the 
brain, the classical pathway contributes to abnormal synaptic pruning in WNV-infected mice as 
evidenced by upregulation of C1QA during disease and neuroprotection in C3-deficient conditions 
(8). In the same study, mice with abnormally low numbers of microglia also exhibited protection 
from this synaptic pruning. On the other hand, the lectin pathway only minimally contributes to 
protection, demonstrated by modestly increased susceptibility in infected MBL-A−/− × MBL-C−/− 
and MASP-2−/− knockout mice versus wildtype controls (91). Comparable experiments designed 
to address the alternative pathway demonstrated faster systemic spread in knockout mice (89). 
WNV proteins also directly affect the complement cascade during infection. WNV NS1 protein 
interferes with full activation of complement by directly associating with Factor H (88). In 
summary, studies of WNV in the CNS reveal a core role for complement in disease progression 
with individual pathways contributing variably to the disease process. 
As neurological complications of DENV infection are rare, the vast majority of research 
connecting complement and DENV are focused in other tissues. DENV can infect hepatocytes 
(major producers of complement) and phagocytes (cellular effectors of complement), altering 
expression of complement-related proteins (4, 92). Notably, complement is an integral component 
of several theories regarding DENV severity, stemming from its potent modulation of antibody 
responses, NS1-induced vascular permeability, and antibody-dependent enhancement. 
Complement activation has been extensively correlated with clinical severity and development of 
vasculopathy characteristic of Dengue hemorrhagic fever and increased levels of anaphylatoxins 
C3a and C5a have been detected in serum of patients with more severe clinical symptoms (3, 93). 
In terms of host genetics, polymorphisms in MBL2 contribute to variation in DENV serum 
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neutralization and associate with the development of severe disease (82). DENV NS1 has also 
been demonstrated to bind complement proteins directly. Interactions with C1Q, C4 and C1S in 
complex, C4BP, C5, C6, C7, C9, MBL, and vitronectin have been reported using techniques 
ranging from immunoassay to affinity purification mass spectrometry (82-87). These interactions 
have functional consequences. For instance, binding of MBL by DENV NS1 abrogates activation 
of the lectin pathway in vitro (82). Similarly, NS1-vitronectin complexes were isolated from 
patient sera and reduce terminal complement complex formation (83).  
Complement in ZIKV infection is modestly characterized in comparison. Complement-
mediated neutralization of ZIKV was demonstrated in normal human serum (85). Intriguingly, 
antibodies binding complement protein C1Q have been identified in the sera of ZIKV-infected 
mice and monkeys, driven by homology between C1Q and ZIKV E protein (94). Furthermore, 
affinity between ZIKV NS1 and C1Q has been reported, mirroring interactions seen in other 
flaviviruses (85). 
Due to complement’s role in early development (differentiation and migration) and 
flaviviral NS1’s capacity to bind complement proteins, it could be hypothesized that ZIKV NS1 
contributes to the cortical disorganization observed in CZS. This possibility was addressed by 
Yoon et al. in supplemental experiments (95). Embryonic mouse cortexes transfected with ZIKV 
NS1 demonstrated no difference in neuroprogenitor cell proliferation (specifically Pax6+ radial 
glial cells) compared to control mice. While this does not entirely preclude involvement of NS1 in 
CZS pathology, the lack of reported defects suggests other viral proteins have a greater 
contribution to neurodevelopmental sequelae. 
The Klein lab has performed highly informative studies evaluating neuroinfection with 
ZIKV and WNV in adult mice (8, 32). Vasek et al. was the initial paper describing complement 
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activation as a molecular mechanism for memory decline post-WNV infection. The following 
study Garber et al. highlights key differences between WNV and ZIKV CNS pathology in their 
mouse model. While WNV was primarily associated with loss of synaptophysin+ (Syp) presynaptic 
termini in the hippocampal CA3 region, ZIKV initiated apoptosis and loss of Homer1+ post-
synaptic termini in neurons. Another major paper evaluating synapse loss in ZIKV-infected adult 
mice, Figueiredo et al. demonstrated similar pathologic findings overall with decreased 
colocalization of pre-synaptic Syp and post-synaptic Homer1 in the CA3 region. Notably, these 
studies used ZIKV strains from different lineages indicating synaptic loss is a conserved feature 
of hippocampal infection. 
As ZIKV and WNV infection lead to divergent synaptic pathologies, pruning-like 
mechanisms in other viral infections are perhaps even less similar. For example, Di Liberto et al. 
demonstrates synapse loss in experimental LCMV infection is not complement-mediated but rather 
a distinct process similarly involving microglia, T cells, and IFN-γ signaling (96). Viral-initiated 
synapse loss appears to generally rely on CD8-derived IFN-γ but not necessarily complement. 
Consequently, it is important not to conflate what happens during infection with what occurs 
during homeostatic pruning or other diseases. Although current understanding hints that pathologic 
pruning involves overactivation of an otherwise conserved complement cascade, there are likely 
multiple pathways leading to synaptic pathology with aspects distinct to each phenomenon. 
This body of research leaves us with several unresolved questions. Is the induction of 
complement-mediated pruning-like mechanisms the “default” outcome in response to viral 
infection? Is initiation of the complement cascade due to binding of viral determinants or triggered 
by the neuron’s cellular state? Are differential outcomes between WNV and ZIKV infections 
related to disparate cytokine profiles, changes in soluble complement / surface-bound complement 
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regulators, or interactions involving complement and viral proteins? Is inhibition of complement 
activation detrimental to adaptive responses in the brain? Based on accumulated evidence, it is 
highly probable complement is involved with adult infection and CZS in some capacity, but the 
clinical relevance of such involvement remains to be determined. 
1.3 Translational Prospects 
Complement therapies are being investigated for efficacy in diverse disease etiologies (97). 
Complement’s extensive, multi-component cascade provides numerous molecular targets for 
intervention. However, investigation into CNS complement could additionally provide novel tools 
for neuroscience research. 
With a conserved role for complement in viral CNS pathogenesis, development of therapies 
applicable to a broad range of neuroinfectious viruses appears feasible. Memory decline and 
learning deficits are common, debilitating symptoms associated with viral CNS infections and 
complement inhibition could have therapeutic benefit across viral families.  
With the current state of CNS complement research, considerably more is known about 
how to inhibit complement-mediated synaptic pruning than how such pruning is initiated (33, 39). 
Study of viral-initiated pruning-like mechanisms could provide insight into this process applicable 
to normal, physiologic conditions or non-viral neurodegenerative diseases. Viral heterogeneity 
could be an advantageous experimental feature. Diverse complement evasion mechanisms exist 
due to selective pressure exerted by serum complement, leading to conserved and non-conserved 
interactions among pathogens which spread via blood. Comparison of these strategies in viruses 
which do and do not induce synaptic damage provide an experimental framework for probing CNS 
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complement regulation. Ideally, such knowledge could be translated to experimental control of 
microglia-mediated pruning. Engineered viruses triggering circuit-specific pruning would clarify 
the contribution of specific synapses to complex cognitive functions or provide therapeutic benefit 
in conditions marked by over-connectivity or over-responsiveness (such as epilepsy or neuropathic 
pain). 
These exciting (albeit distant) translational prospects highlight the potential value of 
studying complement-pathogen interactions in the brain. 
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2.0 Statement of the Project 
The proposed study will clarify the nature of Zika-mediated complement dysregulation 
within the human brain. Experiments aim to validate the applicability of cell lines, characterize 
changes in brain complement during infection, and investigate how these mechanisms could 
contribute to pathology. Each of these aims addresses unknowns in the fields of CNS complement 
and infection. 
Basic science research involving CNS complement predominantly uses mice as 
experimental models. However, complement differs substantially between mice and humans, 
especially in surface-bound inhibitory proteins. Advancements in CNS culturing methodologies 
provide greater representative human models at the cost of great investment (both time and 
money). While characterization of complement in CNS cell lines has been previously conducted 
(25, 98, 99), these results have not been independently validated and uptake of these systems has 
been poor. Consequently, we believe cell lines have utility (albeit limited) in such studies. 
While some aspects of complement during ZIKV CNS infection have been explored (42, 
51), observations only provide a macroscopic view of complement’s involvement. The regulatory 
balance—the interplay between effectors and inhibitors—has not been evaluated. This balance is 
additionally influenced by viral proteins such as NS1. Experiments addressing these factors will 
offer a more granular view of complement-related processes. 
Lastly, precise mechanisms for these processes remain elusive, partially due to difficulties 
associated with in vivo characterization. Our in vitro system and complement-related reagents will 
generate information regarding protein localization and experimental control not seen in previous 
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work. This aim will attempt to tie our observations seen in previous aims to pathogenesis observed 
in vivo. 
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3.0 Specific Aims 
3.1 Specific Aim 1. Identify appropriate in vitro models for assessing complement-virus 
interactions. 
Hypothesis. Development of an appropriate in vitro model will require co-culture of 
multiple cell types: neurons, astrocytes, and microglia. 
Experimental Approach. Initial characterization and co-culture will focus on 
immortalized cell lines comprising neuroblastomas (SH SY5Y) and microglia (HMC3). Using 
established enzyme-linked immunosorbent assays (ELISAs) and flow cytometry, production of 
complement-related proteins will be assessed in single population cultures as well as co-cultures. 
Co-cultures will be established using standard ratios for each population (1:5 - microglia to 
neuroblastoma). 
3.2 Specific Aim 2. Assess viral induced changes in the complement system due to Zika 
infection. 
Hypothesis. Downregulation of complement regulatory molecules and upregulation of 
effectors will occur in Zika CNS infection, mirroring changes seen in the periphery. 
Experimental Approach. ELISAs and flow cytometry will be used to observe 
complement changes in uninfected and infected cells. Existing ELISAs (C1Q, C1R, MBL, C3, 
C3a, C4, C5, C5a, CFH, CFI, C6, C8, and sC5b9) optimized in our lab have been previously 
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validated on reference samples and are highly sensitive. Analogous flow cytometry protocols have 
been established as well (CD11b, CD46, CD55, CD59). ZIKV infection will be performed on SH 
SY5Y/HMC3 co-cultures.  
3.3 Specific Aim 3. Identify mechanisms linking changes in complement-associated proteins 
to pathology. 
Hypothesis. Observed changes in the complement system lead to greater levels of 
neuroblastoma cell death and involves specific localization of complement and Zika NS1. 
Experimental Approach. Expanding on the previous aim, flow cytometry will allow cell 
viability to be assessed across conditions. Confocal microscopy/immunostaining will be used to 
localize complement proteins (C3d, iC3b) to cellular compartments and surfaces. ELISAs will be 
developed to investigate interactions between ZIKV NS1 and complement proteins. Exposure to 
Zika NS1 at a physiologically relevant concentration will also be performed. 
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4.0 Methods 
4.1 Complement Protein Elisas 
High-binding, half-area 96-well plates (Corning, USA) were coated overnight with 
associated antibodies in carbonate-bicarbonate buffer at 4°C in a humid chamber. The next day, 
plates were washed with PBS-T buffer [PBS with 0.05% (v/v) Tween 20]. Plates were blocked 
with bovine serum albumin (Sigma) at 5% (w/v) in PBS for an hour at room temperature (RT; 
21°C to 23°C). A standard curve was generated using purified protein 2-fold serially diluted in 
blocking buffer resulting in 10 points total. Normal human serum (Complement Technology) at a 
protein specific dilution and a dilution buffer blank were included. All dilutions were made in 1% 
(w/v) BSA in PBS Standards, controls, and samples (unaltered cell supernatants) were incubated 
for 2 hour at RT. Plates were washed and incubated for 1 hour at RT with a corresponding mouse 
anti-human protein antibody, purified or conjugated to biotin. For detection, plates were washed 
and incubated for 1 hour at RT with either horseradish peroxidase (HRP)-linked goat anti-mouse 
antibodies or HRP-linked streptavidin. Following additional washes, plates were incubated for 30 
minutes at RT with TMB substrate (KPL, USA) and the reaction was stopped with 1N hydrochloric 
acid (HCl; Sigma). Optical densities at wavelength of 450 nm (OD450) were determined using 
SpectraMax Plus PC380 microplate spectrophotometer using the SoftMax Pro software version 
6.4 (Molecular Devices). Protein concentrations were calculated using 4-parameter non-linear 
regression from the R package ‘drc’ (R version 3.5.3; package version 3.0-1). A list of reagents is 
provided in Appendix A. 
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4.2 ZIKV NS1 Complement Binding Elisas 
High-binding 96-well plates (Corning, USA) were coated with recombinant purified ZIKV 
NS1 (Native Antigen Company) in carbonate-bicarbonate buffer overnight at 4°C. The following 
day, plates were aspirated and tapped on a hard surface to remove excess liquid. Controls with no 
coating step or coated with the corresponding complement protein (1 µg/mL) were included for 
each protein tested. Plates were blocked with bovine serum albumin (Sigma) at 5% (w/v) in PBS 
buffer for an hour at RT. Plates were again aspirated and tapped. Purified complement proteins 
were added to wells at 5 µg/mL. Controls with no protein added were also included, leading to 
four groups – NS1 / protein, protein / blank, blank / protein, and blank / blank (coated protein / 
added protein). All dilutions were in PBS. Samples were incubated for two hours at RT. Plates 
were washed with PBS-T buffer [PBS with 0.05% (v/v) Tween 20] and incubated for 1 hour at RT 
with a corresponding mouse anti-human protein antibody, purified or conjugated to biotin. For 
detection, plates were washed and incubated for 1 hour at RT with either horseradish peroxidase 
(HRP)-linked goat anti-mouse antibodies or HRP-linked streptavidin. Following additional 
washes, plates were incubated for 30 minutes at RT with TMB substrate (KPL, USA) and the 
reaction was stopped with 1N hydrochloric acid (HCl; Sigma). Optical densities at wavelength of 
450 nm (OD450) were determined using SpectraMax Plus PC380 microplate spectrophotometer 
using the SoftMax Pro software version 6.4 (Molecular Devices). Values were represented as the 
ratio of mean OD450 of test samples (NS1 / protein) to experimental controls (blank / protein and 
blank / blank). 
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4.3 Cell Culture 
Cortical organoids and stem cell-derived CNS cells were generously provided by the 
Vishwajit Nimgaonkar lab (Western Psychiatric Hospital, University of Pittsburgh Medical 
Center) (100). SH SY5Y (ATCC® CRL-2266™), HMC3 (ATCC® CRL-3304™), and PHA cell 
lines were generously provided by the Velpandi Ayyavoo lab (University of Pittsburgh Graduate 
School of Public Health).  
For cell lines, bulk cells were grown in flasks and plated on 96 well flat-bottom plates 
(Falcon). In flasks, SH SY5Y cells were maintained in 10% FBS in DMEM:F12K (1:1) media 
while HMC3 cells were maintained in 10% FBS DMEM. When plated in 96 well format, co-
cultures of SH SY5Y and HMC3 were maintained in 7% FBS DMEM. Co-cultures were seeded 
with 3x104 cells in each well with a 1:5 ratio (HMC3:SH SY5Y). Media for 96 well plates were 
collected and changed every 3 days. ZIKV infection was performed at MOI 1 with strain PE243 
(GenBank ref. number KX197192).  Cell supernatants were collected and stored at -20°C until 
use. 
HMC3 and co-culture stimulation with IFN-γ1b was performed with recombinant protein 
(Miltenyi Biotec) at 100 units/mL. After initial administration, subsequent media was also 
supplemented with IFN-γ1b. 
4.4 Flow Cytometry for Complement Related Proteins 
Permeabilization and fixation buffers for intracellular staining were from BD Biosciences. 
Antibodies are as follows: CD11b-PE-Cy7, C5aR-APC, C3aR-FITC, gC1qR-FITC, CD11c-PE, 
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C5L2-PE, CD21-APC, CD59-PE, CD55-PE-Cy7, CD46-APC, goat anti-mouse Alexa Fluor 488, 
and corresponding isotypes. The clone 4G2 anti-flavivirus envelope protein antibody was derived 
from unpurified hybridoma supernatant. 
Isotype controls and unstained negative controls were included with every run. Flow 
acquisition was performed on a BD Biosciences LSR Fortessa Cell Analyzer. Data was acquired 
with FACS Diva software and analyzed using Flow Jo version 10. 
4.5 Imaging Studies 
Brightfield images were obtained with an EVOS XL Core Imaging System and were 
desaturated with an image processing program (GIMP). Millicell EZ chamber slides were seeded 
with 3x104 cells. All washing steps were performed using Hank’s balanced salt solution (HBSS). 
Cells were fixed using acetone and blocked with the appropriate host serum at 5% (v/v). Antibodies 
for immunofluorescence are as follows: C3d (BioLegend Cat. No. 846302), iC3b (Quidel Cat. No. 
A209), and ZIKV NS2B (GeneTex Cat. No. GTX133308). 
4.6 Statistical Analysis 
Statistical analysis was either performed in GraphPad Prism 8.2.1 or R (version 3.6.3) 
(101).  
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5.0 Results 
5.1 Specific Aim 1. Identify appropriate in vitro models for assessing complement-virus 
interactions. 
5.1.1 Complement protein levels in CNS cell models 
ELISAs developed in-house were applied to culture media samples from 2D pluripotent 
stem cell-derived CNS cells, 3D cortical brain organoid cultures, and immortalized cell lines. 
Cortical brain organoid media had undetectable levels for all tested proteins (C1q, C3, C5, C8, 
SC5b9, CFH; data not shown).  Other surveyed supernatants with detected complement were 
largely limited to detection of C3 although other complement proteins were detected (Figure 5). 
Later evaluations of soluble complement levels using media from 96 wells demonstrated improved 
detectable ranges compared to media from flasks. 
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Figure 5 Detection of Complement Proteins in media of CNS Cell Lines 
Culture media from cell culture flasks were subjected to various ELISAs. Values are derived from pooled experimental 
replicates (n = 2) with two technical replicates each. Normal human serum was included as a positive control. NHS – 
normal human serum. 
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Figure 6 Co-culture of Stem Cell-derived CNS Cells Alters C3 Levels in Supernatant 
Levels of C3 in Stem Cell-derived CNS cell supernatant were determined in monocultures and co-cultures. Values 
were adjusted for the number of microglia initially seeded. Bars represent the median and quartiles. 
 
In differentiated cells and cell lines, microglia appeared to be the sole producers of C3 in 
culture (Figure 6). Notably, co-culture of differentiated microglia and neurons enhanced C3 
production after adjustment for number of microglia. Additionally, complement detection in co-
cultures of differentiated cells and of cell lines SH SY5Y and HMC3 were perfectly correlated. 
HMC3 cells and SH SY5Y / HMC3 co-cultures were stimulated with IFN-γ1b at 100 
Units / mL. No changes in complement levels (C1q, C3, C3a, C5, CFH, CFB) were observed at 
day 3 and day 5 timepoints (data not shown). 
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5.1.2 Complement receptors and regulators in SH SY5Y, HMC3, and hNPCs 
Various antibody cocktails were developed to investigate complement-related surface 
proteins on SH SY5Y, HMC3, and hNPCs using flow cytometry. Levels of proteins were evaluated 
on live, singlet cells and compared to an isotype control.  
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SH-SY5Y and HMC3 demonstrated all three complement regulators on cell surfaces 
(Figure 7). In comparison, hNPCs expressed lower levels of CD46 and CD59 and did not exhibit 
CD55. The presence of these regulators under typical culture conditions allows for the detection 
of changes in infected cultures. 
 
Figure 7 Cell Surface Complement Regulators on SH SY5Y, HMC3, and hNPCs 
Flow cytometry plots depicting fluorescence intensity for CD46, CD55, and CD59 on various cell types. 
Expression was evaluated on live, singlet cells.  
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Additional complement-related surface proteins were assessed on SH SY5Y cells (Figure 
8). Of these additional proteins, modest expression of gC1qR and C5L2 was detected. In summary, 
surface complement-related proteins are largely limited to regulatory molecules which are present 
on both SH SY5Y and HMC3 cells.  
Figure 8 Complement-related Proteins on SH SY5Y Cells 
Flow cytometry plots depicting fluorescence intensity for gC1qR, CD46, CD55, CD59, C3aR, C5L2, 
C5aR, CD11b, CD21, CD11c, CD16, and CD32 on unstimulated SH SY5Y cells. Expression was 
evaluated on live, singlet cells. 
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5.1.3 Infection of HMC3 with ZIKV 
While ZIKV infection of SH SY5Y cells has been reported in previous studies, HMC3 
infection has not been studied (102). ZIKV infection of unstimulated HMC3 was assessed at 
MOI 1 by immunostaining (Figure 9).  
 
Figure 9 ZIKV Infection of HMC3 
Immunostaining for ZIKV Envelope protein (Alexa Fluor 488) taken with a 40x objective. 
 
Although HMC3 cells demonstrated extensive infection with immunostaining, infection 
was difficult to detect in live HMC3 cells using flow cytometry (data not shown). At 5 DPI, 
HMC3 cells demonstrated cytopathic effect with brightfield microscopy. Compared to mock 
infected cells, ZIKV exposed HMC3 were greatly depleted in culture (Figure 10).  
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Figure 10 ZIKV Cytopathic Effect in HMC3 Cells 
Brightfield microscopy images of ZIKV-infected HMC3 cells taken with a 10x objective. Scale bar is 400 µm.  
5.1.4 Establishment of an SH SY5Y / HMC3 co-culture 
Initially, co-cultures with SH SY5Y, HMC3, and an astrocytic cell line were evaluated. 
However, the inclusion of immortalized astrocytes PHA lead to dense cellular clumps in culture 
flasks centered around astrocytes (Figure 11). As such clumps may compromise cellular viability 
and impede downstream flow analysis, astrocytic cell lines were excluded from subsequent  
experiments. SH SY5Y / HMC3 co-cultures (5:1 ratio) were established with both cell types 
capable of growth in a common medium (7 or 10% FBS in DMEM). 
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5.2 Specific Aim 2. Assess viral induced changes in the complement system due to Zika 
infection. 
5.2.1 ZIKV-induced changes in soluble C3 levels 
Levels of soluble complement factors were assessed after infection of cultures. C1q, C5, 
CFB, CFH, and CFI remained undetectable post-infection (data not shown). However, C3 retained 
detectable levels (Figure 12). 
 
Figure 11 Inclusion of an Astrocytic Cell Line Leads to Cellular Aggregates 
Brightfield microscopy of SH SY5Y, HMC3, and PHA co-cultures A) In regions without astrocytes, co-cultures 
develop in a flat monolayer. B) Other regions have dense cellular aggregates centered around astrocytes. A was 
taken with a 40x objective while B was taken with a 10x objective.  
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The dynamics of C3 during infection differ between HMC3 monocultures and SH SY5Y / 
HMC3 co-cultures. While both HMC3 and co-cultures demonstrated increases in C3 from day 3 
to 5, infected co-cultures had reduced soluble C3 in comparison to matched mock controls, an 
observation absent in infected HMC3 monocultures. This reduction could represent greater 
cleavage of C3 or a decline in C3 production in co-cultures.  
5.2.2 ZIKV-induced changes in surface-bound complement-related proteins 
Unstimulated HMC3 monocultures were infected with ZIKV and analyzed 5 days post 
infection (DPI) for surface expression of CD11b, CD46, and CD59 (Figure 13). For CD11b, two 
distinct populations emerge: CD11b+ and CD11b- groups. ZIKV infection appears to induce the 
Figure 12 C3 Levels during ZIKV Infection of HMC3 and Co-cultures 
C3 levels in infected and mock cultures were assessed by ELISA at 3 and 5 days post infection (DPI). Values 
are derived from pooled experimental replicates (n = 2) with two technical replicates each. 
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expression of CD11b in some HMC3 while downregulating it in others. In contrast, reduction only 
of CD46 and CD59 was observed in exposed cultures.  
 
 
 
Unstimulated SH SY5Y monocultures and SH SY5Y / HMC3 co-cultures were infected 
with ZIKV and analyzed at 5 DPI for changes in surface-bound complement regulators CD46, 
CD55, and CD59 (Figure 15). Staining for ZIKV envelope protein allowed for differentiation of 
actively infected or non-infected cells within the ZIKV-exposed culture. A representative plot 
showing the gating strategy of an exposed co-culture is depicted in Figure 14. 
Figure 13 Changes in CD11b, CD46, and CD59 in Infected HMC3 Cells 
Flow cytometry plots depicting fluorescence intensity for CD46, CD59, and CD11b on ZIKV-infected HMC3 
and Mock cells. Expression was evaluated on live, singlet cells. 
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Figure 14 Gating Strategy for Analysis of ZIKV-Infected Co-cultures 
A representative plot demonstrating the gating strategy for ZIKV-infected co-cultures of SH SY5Y and HMC3. 
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Figure 15 Changes in Cell Surface Complement Regulators CD46, CD55, and CD59 During ZIKV Infection 
A) Co-culture of ZIKV Infected SH-SY5Y with HMC3 reduces overall cell viability. While viability did not 
significantly differ for SH-SY5Y mono-culture, differences in mean viability between mock and infected co-cultures 
were observed (76.5% vs 61.2%). At an MOI of 1, ZIKV infection resulted in an average of 17.1% (SH-SY5Y; n = 
3) and 21.3% (SH-SY5Y + HMC3 [5:1 ratio]; n = 6) infected cells. B) CD46 is upregulated on ZIKV infected cells 
while CD55 is downregulated in both infected and bystander cells. ANOVA was performed followed by Tukey’s 
multiple comparisons test. Multiplicity adjusted p-values are reported. * denotes p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, 
and **** p ≤ 0.0001. 
 
In co-cultures, CD46 is upregulated on ZIKV infected cells while CD55 is downregulated 
in both infected and bystander cells. The upregulation of CD46 could preferentially generate 
iC3b on infected cells, leading to CR3-mediated synaptic pruning but protection from further 
complement activation. The downregulation of CD55 could allow destruction of infected and 
bystander cells if terminal complement components make it past the blood brain barrier. 
 43 
5.3 Specific Aim 3. Identify mechanisms linking changes in complement-associated proteins 
to pathology. 
5.3.1 Visualization of C3d and iC3b deposition on co-cultures 
To visualize the impact of altered surface complement regulators, immunostaining with 
antibodies for C3d (which recognizes an epitope present on C3, C3b, iC3b, and C3d) and iC3b. 
 
 
C3d staining was minimal (likely due to a sub-optimal antibody concentration) on both 
mock and ZIKV-exposed co-cultures (Figure 16). On the other hand, iC3b staining visibly 
appeared greater in exposed vs mock cultures (Figure 17). Qualitatively, iC3b staining appeared 
brighter in association with infected cells, an expected result based on CD59 downregulation and 
CD46 upregulation. 
Figure 16 Immunostaining for C3d on ZIKV-infected Co-cultures 
A representative field depicting immunostaining of acetone-fixed co-cultures cultures in chamber slides. Mock 
and infected cultures demonstrated similar levels of C3d. Images were captured with a 40x objective. 
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5.3.2 Evaluation of binding between ZIKV NS1 and complement proteins 
As several interactions between flaviviral NS1 and complement components have been 
reported, we sought to investigate ZIKV NS1-complement associations using an ELISA. 
Figure 17 Immunostaining for iC3b on ZIKV-infected Co-cultures 
A representative field depicting immunostaining of acetone-fixed co-cultures cultures in chamber slides. Mock 
and infected cultures demonstrated similar levels of C3d. Images were captured with a 40x objective. 
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C3, C3a, and SC5b9 (soluble polymerized complement factors 5 through 9) demonstrated 
some degree of affinity with NS1 (Figure 18). The greater levels of bound C3a suggests cleavage 
of C3 may reveal a binding site with high affinity for NS1. Additionally, binding of multimeric 
SC5b9 complexes could be due to a specific component of the terminal complement complex. 
As flaviviral NS1-complement interactions have functional consequences, further experiments 
examining these interactions in the context of complement activation are warranted. 
Figure 18 ZIKV NS1 Binding of Complement Proteins 
ZIKV NS1 binds complement components. Binding was detected using an ELISA with ZIKV NS1 coated wells 
exposed to various complement components. Each condition was run with three technical replicates. The y axis is 
the ratio of mean OD450 of test samples (NS1 coated / protein added) to experimental controls (blank coated / 
protein added and blank coated / blank added). 
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5.3.3 Exposure of SH SY5Y and HMC3 to purified recombinant ZIKV NS1 
Previous studies indicated that macrophage exposure to DENV NS1 in co-culture could 
elicit inflammatory transcriptional changes (103). We sought to test if exposure to ZIKV NS1 was 
sufficient to induce the changes in surface complement regulators seen during infection (Figure 
19). 
 
 
ZIKV NS1 treatment does not affect the expression of C3aR, CD46, CD55, and CD59. 
SH-SY5Y and HMC3 cells exposed to 6 μg/mL of purified, recombinant ZIKV NS1 demonstrated 
no change in viability (not shown) or expression of select complement-related proteins.  
 
Figure 19 ZIKV NS1 Treatment of SH SY5Y and HMC3 Cells 
ZIKV NS1 treatment does not affect the expression of C3aR, CD46, CD55, and CD59. Flow cytometry plots 
depicting fluorescence intensity for C3aR, CD46, CD55, and CD59 on ZIKV NS1-exposed SH SY5Y and HMC3 
cells. Expression was evaluated on live, singlet cells. 
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6.0 Discussion 
Aim 1 involved the establishment of an in vitro model of CNS complement production. 
Cell lines were capable of modeling infection and expressed the central complement protein, C3.  
In line with previous research, infection was detected in both SH SY5Y and HMC3 cell 
lines at an MOI of 1 (102, 104, 105). While ZIKV-exposed HMC3 cells were greatly depleted in 
culture, SH SY5Y did not demonstrate a cytopathic effect with comparable viabilities between 
mock and exposed cultures. Accordingly, percentages of infected cells increased and overall 
viability decreased when HMC3 were introduced into infected co-cultures.  Depletion of HMC3 
cells may complicate interpretation of results, especially at later time points. As HMC3 are the 
main producers of several complement proteins, declines in detectable levels may be due to 
depletion of HMC3 rather than increased degradation through activation. Overall, the co-culture 
of SH SY5Y and HMC3 represents a viable system to assess viral-induced changes in the 
complement system. 
Many complement proteins expressed in the periphery were undetectable in various CNS 
co-culture models. C3 was the only key complement protein detected, limiting activation to C3 
tickover. The Fontaine lab previously validated complement production in several CNS cell lines 
in monoculture (18, 77-79). However, our results are discordant. While many of the Fontaine 
studies demonstrate production of several complement proteins at the protein and mRNA level, 
we detected only select complement factors in the various systems surveyed. Particularly, our 
ELISAs were unable to detect terminal components C6, C8, C9 despite high sensitivity. Based on 
such drastic discordance, we speculate that production of complement by cell lines is potentially 
subject to culture conditions. Additionally, cellular populations capable of directly producing or 
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stimulating production of these missing proteins may have been excluded from the existing co-
culture. As such, CNS complement production remains ambiguous. Further in vitro studies are 
needed to clarify soluble factors and cell populations responsible for complement production.  
Based on results, it appears that the use of cell lines in lieu of more advanced cell models 
is feasible. Production of complement proteins in cell line co-cultures and iPSC-derived co-
cultures were perfectly correlated. While cell lines are generally less representative, the substantial 
effort required to maintain iPSC-derived cultures can be mitigated with usage of both systems in 
tandem. Validation with more advanced culture systems is still warranted as cancerous cells can 
co-opt complement signaling to promote survival, potentially confounding experiments (106).  
Finally, the use of astrocytic cell lines was abandoned. The inclusion of immortalized 
astrocytes in co-culture lead to cell aggregates in culture. As astrocytes likely play an important 
role in ZIKV infection and in complement production, alternative culture techniques should be 
explored. 
Aim 2 assessed the impact of infection on complement production and regulation. 
Although ZIKV infection upregulated complement components in immortalized hepatocytes and 
placental trophoblasts (not shown), similar findings were not seen in CNS cell lines. C3 levels 
were decreased in infected co-cultures but not HMC3 cultures compared to mock exposed controls 
at 5 DPI. This reduction in soluble C3 could be tied to greater activation or decreased production 
by HMC3 in co-culture. As iC3b appears greater in infected co-cultures and infected HMC3 
monocultures did not exhibit the same pattern, this is likely due to increased cleavage of C3 via 
C3 tickover and not decreased production through HMC3 depletion. Despite this, measurement of 
soluble C3a levels would be an appropriate follow-up experiment to confirm greater activation in 
co-culture. 
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The complement regulators CD46, CD55, and CD59 were altered by ZIKV infection. The 
dynamics of CD46 and CD55 imply CD46 upregulation is a direct consequence of viral infection 
while CD55 downregulation is mediated by soluble factors released into culture. These changes 
could lead to different functional fates for bystander and infected neuroblastoma cells.  
CD55 downregulation alone was observed in neuroblastoma bystander cells. CD55 
downregulation allows for the accumulation of C3 convertase on cell surfaces and subsequent 
deposition of C3b fragments. If terminal complement components are present, deposition will 
trigger the formation of the terminal complement complex, lysing the C3b tagged cell. Moreover, 
C3b and downstream iC3b have been implicated in synaptic pathology (6).  Consequently, 
decreased CD55 in vivo might contribute to loss of viable, un-infected neurons or their synapses. 
Both an increase in CD46 and decrease in CD55 surface protein was detected on ZIKV-
infected SH SY5Y cells. Coupled with increased deposition of C3b through CD55 downregulation, 
CD46 upregulation is hypothesized to increase generation of iC3b as CD46 is a cofactor for 
proteolytic CFI. This is supported by the qualitative association of iC3b and infection detected by 
immunostaining. The functional relevance of this finding is difficult to determine in culture. In the 
periphery, iC3b recognition by complement receptors, primarily CR3 (composed of CD11b and 
CD18), induces phagocytosis. Phagocytosis of infected CNS cells could contribute to patterning 
of downstream adaptive responses as well as pruning of synapses on infected cells. iC3b-induced 
phagocytosis by antigen presenting cells leads to antigenic tolerance via anti-inflammatory 
cytokine production outside the CNS (107). Analogous roles in the brain could influence T cell 
activation status in the CNS antiviral response, delaying clearance. While phagocytosis of infected 
cells was not evaluated in this study, functional in vitro assays exist and could address this 
possibility. Additionally, C3b and possibly iC3b are believed to tag synapses for removal through 
 50 
CR3 (6). Increased production of iC3b through CD46 could provide a mechanism for pruning of 
infected cell synapses observed in mice models (Figure 20).  
 
 
It is unclear how these changes reconcile with loss of post-synaptic but not pre-synaptic 
termini observed in Garber et al. (51). Mice lack CD46 on most cells but express Crry, a functional 
analog of CD46 in rodents (107). Furthermore, the distribution of complement inhibitors varies 
considerably between mice and humans. As such, mice models are greatly limited in their 
Figure 20 Changes in Surface-bound Complement Inhibitors During ZIKV Infection 
Changes in surface regulators could lead to different functional fates for infected and bystander SH SY5Y cells. 
ZIKV NS1 could additionally impact cell fate through interactions with complement proteins. CD55 downregulation 
allows for deposition of C3b as CD55 antagonizes the alternative pathway (AP) convertase. CD46 upregulation 
leads to increased CD46 by serving as a cofactor for CFI. 
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generalizability to human infection and investigation of similar phenomena in mice models will 
be restricted. 
For HMC3 monocultures, decreases in CD46 and CD59 were detected in infected cultures, 
mirroring observations seen in DENV infected hepatocytes (Unpublished). Additionally, CD11b+ 
and CD11b- populations appeared during ZIKV infection. As reduction of CD59 and CD11b has 
been reported previously in DENV-infected peripheral monocytes (92), such downregulation 
appears to be conserved across flaviviral infection of professional phagocytes. In prior, 
unpublished studies with hepatocytes, these changes were restricted to bystander but not infected 
cells and we hypothesize that HMC3 infection is similar. Such changes (tied to phosphorylation 
of STAT3 in the unpublished work) may represent a more general response to flaviviral infection 
that does not occur in SH SY5Y cells. 
As expected, ZIKV NS1 appears to bind complement components C3, C3a, and SC5b9. 
The greater affinity for C3a than C3 suggests cleavage reveals a binding site, leading to stronger 
interactions. Binding of SC5b9 could be due to one or several of the proteins in the multimeric 
complex. Finally, ZIKV NS1 treatment did not induce changes in complement regulators. NS1 in 
absence of infection is capable of triggering pathological changes.  As NS1 binding perturbs 
complement activation, future studies could elucidate ZIKV NS1’s involvement in CNS 
pathology. 
In conclusion, the above study has established a working CNS co-culture model to assess 
flaviviral-induced changes in the complement system. Additionally, results describe previously 
unreported changes in several regulatory molecules which occur in a cell specific manner. Further 
investigation supporting these preliminary findings and linking observations to pathology are 
needed. 
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7.0 Public Health Significance 
Zika virus is a positive-strand RNA virus of the family Flaviviridae typically causing mild 
to inapparent infection (43). While the existence of Zika was known since 1947, the virus remained 
obscure until the World Health Organization declared an international health emergency during 
the Brazilian outbreak. The explosive nature of the pandemic and rapid subsequent decline of cases 
has led to uncertainty regarding potential future outbreaks. With the continually expanding 
geographical range of Zika’s primary vector (the Aedes species mosquito), threat of re-emergence 
persists (108). 
Despite Zika’s decline, ongoing circulation and spread have been demonstrated (109, 110). 
A recent report indicated a 2018 outbreak in Cuba went largely un-noticed and un-reported to local 
and global public health agencies (110). Such “hidden” epidemics are possible due to Zika virus’ 
propensity for inapparent infection and current limitations in diagnostics and surveillance. 
Considering these factors, evaluation and development of vaccines and therapies are essential for 
future epidemic preparedness.  
Outbreaks of Zika are particularly concerning with the increased incidence of severe 
neurological symptoms among both neonates and adults during the 2015 Zika outbreak (1, 2). For 
neonates, congenital Zika syndrome describes an amalgamation of potential findings associated 
with maternal infection, ranging from neurodevelopmental delay (in absence of overt physical 
defects) to microcephaly (111-113). Exposed neonates may appear un-affected at birth but require 
care later in life. For adults, neurological complications are typified by ZIKV-associated Guillain-
Barré syndrome. Emerging evidence additionally associates adult CNS infection with memory 
decline, mirroring observations in West Nile virus CNS infection (8, 42, 51). Long-term care of 
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affected individuals imposes substantial financial and emotional burden on individuals, families, 
and health systems (114). 
Death of neurons is observed in both adult and congenital infection, likely related to 
development of neurologic sequelae (67, 115). The complement system has recently been tied to 
severity of Zika CNS infection (42, 51). A series of serum proteases sequentially activated through 
enzymatic cleavage, complement’s traditional functions comprise tagging pathogens for lysis, 
phagocytosis, and opsonization. In recent years, complement has demonstrated other emerging 
roles including regulation of cell metabolism, detection of intracellular pathogens, synaptic 
pruning, and neuronal differentiation. The link between complement and flaviviral CNS infection 
fits into a larger constellation of neurodegenerative diseases such as stroke, schizophrenia, 
Alzheimer’s, Lyme disease, and HIV-associated neurocognitive disorders (10, 20, 116-118). 
While investigation of complement in Zika CNS infection is specific, investigation will likely 
produce general insights into how complement functions in the brain—insights which will improve 
our understanding of neurodegeneration. 
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8.0 Future Directions 
Substantial gaps remain concerning interactions between ZIKV infection and complement. 
The proposed experiments would contextualize our existing findings.  
1. Assess the influence of cytokines on complement secretion and correlation with 
microglial activation in vitro. 
2. Intracellular staining of complement proteins in CNS culture systems. 
3. Replication of phenomena (surface-bound complement modulation) in more robust 
CNS cell models such as differentiated pluripotent stem cells. 
4. Validation of ZIKV NS1 interactions with complement proteins and characterization 
of functional consequences during infection. 
5. Analogous experiments with DENV or attenuated WNV. 
6. Treatment of cultures with complement therapeutics (compstatin, cobra venom factor) 
to identify changes in cell viability or viral load. 
More broadly, investigation of virally induced synaptic pruning would benefit from 
comparing viruses restricted to hematogenous spread (such as ZIKV and WNV) to viruses capable 
of trans-synaptic transport mechanisms (rabies, pseudorabies, and herpes simplex virus 1 [HSV1]). 
Intuitively, viruses capable of retrograde or anterograde axonal transport may experience selection 
for synapse preservation rather than loss, particularly HSV1 which relies on latent reactivation for 
communicability. Comparing CNS infections would provide a framework for understanding 
molecular changes necessary for pruning-like mechanisms.  
While C3 and C1q knockout mice demonstrate greater synaptic density compared to 
wildtype mice, reciprocal experiments evaluating knockout or knockdown of surface-bound 
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inhibitors (such as Crry) have yet to be performed.  While increased levels of brain complement 
are likely contributors to pathology under the highly inflammatory conditions of viral infection, it 
is unclear if downregulation of complement regulatory molecules coupled with homeostatic 
complement levels is equally capable of triggering synapse loss. Performing these studies would 
clarify the contributions of both increased activation and decreased inhibition to pathology. 
Establishment of these models is arduous due to embryonic lethality; however, such mice have 
been previously generated but not had synaptic connectivity evaluated (119). 
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Appendix Complement ELISA Reagents 
Appendix Table 1 Capture Antibodies 
# Target 
Capture ab 
Clonality/Host 
Cat# / 
Manufacturer 
Dilution 
1 C1q pab/Goat antisera A301 / Quidel 1:5,000 
2 C3 pab/Goat antisera 
A213 / 
Complement 
technology 
1:500 
3 CFH pab/Goat antisera 
341276/ 
Calbiochem 
1:500 
4 CFI pab/Goat antisera 
A238 / 
Complement 
technology 
1:500 
5 CFB mAB/Mouse (clone KT21) 
ab110651 / 
Abcam 
1:250 
7 C5 pab/Goat antisera A306 / Quidel 1:500 
8 C6 pab/Goat antisera A307 / Quidel 1:500 
9 C8 pab/Goat antisera A309 / Quidel 1:500 
11 SC5b-9 pab/Rabbit antisera 
A227 / 
Complement 
technology 
1:500 
12 Oligomer MBL mAB/Mouse (clone 3B6) 
BPD-HYB-131-
01 / Enzo Life 
sciences 
1:1,000 
13 C5a mAB/Mouse 
Part 842755 / 
R&D systems 
1:180 
14 C1r pab/Sheep IgG 
LS-C22276/ 
LSBio 
1:500 
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Appendix Table 2 Standard Curve 
# Target 
Standard Curve 
Range 
(ng/mL) 
Fold 
dilution       
(# points) 
Cat# / 
Manufacturer 
Stock 
conc. 
(mg/mL) 
Serum dilution 
1 C1q 200-0.2 2 (11) A400/Quidel 1 5,000-10,000X 
2 C3 500-0.1 2 (11) A401/Quidel 1 20,000X 
3 CFH 1,000-1 2 (6) A410/Quidel 1 2,500-5,000X 
4 CFI 4,000-4 2 (11) 
A138/Complement 
technology 
1 250-500X 
5 CFB 1,000-30 2 (6) A408/Quidel 1 1,250X 
7 C5 1000-2 2 (10) A403/Quidel 1 500-1,000X 
8 C6 10-0.01 2 (11) A404/Quidel 1 5,000X 
9 C8 100-0.1 2 (11) A406/Quidel 1 1,000X 
11 SC5b-9 1000-15 2 (7) 
A127/Complement 
technology 
1 25X-100X 
12 
Oligomer 
MBL 
40-0.08 2 (10) 
2307-MB/R&D 
systems 
0.1 100X 
13 C5a 0.2-0.03 2 (7) 
Part 842757/R&D 
Systems 
0.00013 1,000X 
14 C1r 4,000-32 2 (8) 
A102/Complement 
technology 
1 125-250X 
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Appendix Table 3 Detection Antibody 
# Target 
Detection ab 
Clonality/Host Cat# / Manufacturer Format Dilution 
1 C1q 
mab/Mouse 
IgG1 
sc-53544/Santa Cruz Purified 1:4000 
2 C3 pab/Rabbit IgG ab48342/Abcam Biotin 1:1,000 
3 CFH 
mab/Mouse 
(clone OX23) 
ab17928/Abcam Purified 1:10,000 
4 CFI 
mab/Mouse 
IgG (clone 
9E11) 
NBP1-05071/Novus 
Biologicals 
Purified 1:1,000 
5 CFB 
mab/Mouse 
IgG 
A712/Quidel Biotin 1:500 
7 C5 
mab/Mouse 
IgG1 
ab17457/Abcam Purified 1:5000 
8 C6 
mab/Mouse 
IgG 
A219/Quidel Purified 1:1,000 
9 C8 
mab/Mouse 
IgG 
A249/Quidel Purified 1:1,000 
11 SC5b-9 
mab/Mouse 
IgG 
A711/Quidel Biotin 1:500 
12 
Oligomer 
MBL 
mab/Mouse 
IgG (clone 
3B6) 
BPD-HYB-131-01B/Enzo 
Life sciences 
Biotin 1:2000 
13 C5a 
mab/Mouse 
IgG 
Part 842756/R&D Systems Biotin 1:180 
14 C1r mab/IgG2b MAB1807/R&D Systems Purified 1:250 
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Appendix Table 4 HRP Conjugated Antibody 
# Target 
HRP-labeled protein 
Host Cat# / Manufacturer Dilution 
1 C1q Goat 115-036-006/Jackson Imuno 1:2000 
2 C3 Streptavidin S000-03/Rockland 1:20,000 
3 CFH Goat 115-036-006/Jackson Imuno 1:2000 
4 CFI Goat 115-036-006/Jackson Imuno 1:2000 
5 CFB Streptavidin S000-03/Rockland 1:20,000 
7 C5 Goat 115-036-006/Jackson Imuno 1:2000 
8 C6 Goat 115-036-006/Jackson Imuno 1:2000 
9 C8 Goat 115-036-006/Jackson Imuno 1:2000 
11 SC5b-9 Streptavidin S000-03/Rockland 1:20,000 
12 
Oligomer 
MBL 
Streptavidin S000-03/Rockland 1:20,000 
13 C5a Streptavidin S000-03/Rockland 1:20,000 
14 C1r Goat 115-036-006/Jackson Imuno 1:2000 
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